
Contineum Therapeutics Reports Q2 2026 Financial Results, Reaffirms Key Clinical Development Milestones
Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones Contineum Therapeutics, Inc. a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today reported its second-quarter 2026 financial results…














